110P - Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Alexandra Canonici
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors A. Canonici1, M.F..K. Ibrahim1, K. Fanning1, M. Cremona2, C. Morgan2, B. Hennessy2, F. Solca3, J. Crown4, N. O'Donovan1
  • 1National Institute For Cellular Biotechnology, Dublin City University, 9 - Dublin/IE
  • 2Medical Oncology Lab., Dip. Molecular Medicine, Royal College of Surgeons in Ireland, 9 - Dublin/IE
  • 3Pharmacology And Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna/AT
  • 4Dept Of Medical Oncology, St Vincents University Hospital, 4 - Dublin/IE



Triple negative breast cancer (TNBC) lacks expression of hormone receptors and amplification of HER2. There are currently no approved targeted therapies. EGFR is frequently overexpressed in TNBC and may be a rationale target. The activity of afatinib, an irreversible pan-HER TKI, was assessed alone and in combination with inhibitors of other promising targets for TNBC.


Sensitivity to afatinib and other targeted therapies was assessed using proliferation assays. IC50 and CI values were determined using CalcuSyn. Statistical analyses were performed on StatView software. Proteomic profiling was performed by Reverse Phase Protein Array (RPPA).


As previously shown (Ibrahim et al, ASCO 2014), the IC50 values for afatinib in 14 TNBC cell lines ranged from 0.007-5.0 µM. 3 of the 7 basal-like cell lines were sensitive to afatinib (IC50 


Afatinib in combination with dasatinib may have activity in TNBC. Bcl2 may be a predictive biomarker to identify patients who are more likely to benefit from this combination. RPPA results suggest that efficient inhibition of both ERK and Akt signalling may contribute to the synergistic anti-proliferative effects of afatinib combined with dasatinib.

Clinical trial identification

Legal entity responsible for the study

Dublin City University


Boehringer Ingelheim


A. Canonici, N. O'Donovan: Received research funding from Boehringer Ingelheim. F. Solca: Eployee of Boehringer Ingelheim. J. Crown: Received research funding from Boehringer Ingelheim; and travel, accommodation and expenses from Bristol-Myers Squibb. All other authors have declared no conflicts of interest.